# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ella Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML029-SYN-TD
- Date: 1987-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odessa Whitlow, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk. **S**

## Historical basis

- Ella Jane Fitzgerald was born on April 25, 1917, in Newport News, Virginia, to Temperance and William Fitzgerald. Most biographies gave 1918, but her birth certificate and school records show 1917. **D**
- In 1932 her mother died suddenly of a heart attack; orphaned at 15, she was placed in the Colored Orphan Asylum in Riverdale, New York. **D**
- In 1934 she won an amateur contest at the Apollo Theater in Harlem, which brought her to the attention of the drummer and bandleader Chick Webb; she made her first recording with his band in 1935, and her 1938 swing version of the nursery rhyme "A-Tisket, A-Tasket" became her first hit. **D**
- She won the Grammy Award for Best Jazz Individual Performance in 1958 for Ella Fitzgerald Sings the Duke Ellington Song Book, and received the Kennedy Center award for lifetime achievement in 1979. She was known as America's first lady of song. **D**
- She began to have health problems during the 1970s; she had diabetes, which caused problems with her eyes. **D**
- In the 1970s, after cataract surgery, she returned to touring more than 40 weeks a year. **D**
- In 1986 she was admitted to intensive care for heart trouble and underwent quintuple-bypass heart surgery; the following year she was back onstage. **D**

6 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legs. **S**
- Her glucose has dropped low after late shows, once just before an encore. **S**
- The vision in her right eye has blurred, and she worries about reading lyrics and set lists. **S**

## Strengths and supports

- Supports and strengths: her music, her audiences, her band and road manager, and decades of experience of her own body on the road **S**

## Medications and allergies

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals **S**
- Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime **S**
- Insulin glargine 100 units/mL pen, 24 units under the skin each morning **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth each morning **S**
- Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1970s: Diabetes affecting her eyes, with health problems beginning in the 1970s **D** (CLM-0007)
- 1970s: Cataract surgery, after which she returned to touring more than 40 weeks a year **D** (CLM-0008)
- 1986: Intensive care admission for heart trouble and quintuple-bypass heart surgery **D** (CLM-0009)

## Procedures and immunizations

- No procedures before this visit. **S**


## Family history

- mother: Died suddenly of a heart attack in 1932; age at death not recorded in the cited source **D** (CLM-0002)

## Measurements

Hemoglobin A1c: 8.6% (high); Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 0.92 mg/dL; eGFR: 67 mL/min/1.73 m²; Glucose: 168 mg/dL (high); Urine albumin-creatinine ratio: 18 mg/g; Total cholesterol: 164 mg/dL; LDL cholesterol: 92 mg/dL; HDL cholesterol: 44 mg/dL (low); Triglycerides: 140 mg/dL; ALT: 22 U/L; AST: 24 U/L; Hemoglobin: 12.4 g/dL; Vitamin B12: 386 pg/mL; Ankle-brachial index, right: 0.62 (low); Ankle-brachial index, left: 0.74 (low); Toe-brachial index, right: 0.46 (low); Toe-brachial index, left: 0.55 (low); Best-corrected visual acuity, right eye (ETDRS letters): 64 (low); Best-corrected visual acuity, left eye (ETDRS letters): 81. All results are synthetic.

BP 126/70 mmHg; pulse 62 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 84 kg; BMI 30.9 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, warm, and engaged; worried about her legs and her eyes and determined to keep performing. Functional status: Independent in all activities of daily living; walks about one and a half blocks before calf pain stops her; uses a wheelchair in large airports; stands through 75-minute sets. Physical examination is intentionally limited. **S**

## Assessment

1. Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications; status draft. **S**
2. Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems; status draft. **S**
3. Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery; status draft. **S**

## Plan

- Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change. Guideline: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissue. Guideline: The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%). Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin. Guideline: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026) **S**
- Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring. Guideline: Standards of Care in Diabetes—2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**

## Guideline basis

- Standards of Care in Diabetes—2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes Metab Res Rev 2024)
- The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023), IWGDF, European Society for Vascular Surgery, and Society for Vascular Surgery (Diabetes Metab Res Rev 2024)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026), Aether Forge
